The apparent increased sensitivity of BRAF-mutated tumors to a CMV-related preventative effect is consistent with BRAF-mutated melanomas invoking an immune response distinct from that of BRAF-WT tumors, with reduced CD8+ T cell infiltration57 and improved outcomes to cICB47. The gene discussed is BRAF; the disease is melanoma.